HomeCompareAMTI vs ORCC

AMTI vs ORCC: Dividend Comparison 2026

AMTI yields 760.46% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMTI wins by $1810669.94M in total portfolio value
10 years
AMTI
AMTI
● Live price
760.46%
Share price
$0.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1810669.96M
Annual income
$1,438,546,236,154.04
Full AMTI calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — AMTI vs ORCC

📍 AMTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMTIORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMTI + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMTI pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMTI
Annual income on $10K today (after 15% tax)
$64,638.78/yr
After 10yr DRIP, annual income (after tax)
$1,222,764,300,730.93/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, AMTI beats the other by $1,222,764,300,730.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMTI + ORCC for your $10,000?

AMTI: 50%ORCC: 50%
100% ORCC50/50100% AMTI
Portfolio after 10yr
$905334.99M
Annual income
$719,273,118,077.54/yr
Blended yield
79.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

AMTI
Analyst Ratings
3
Hold
2
Sell
Consensus: Hold
Price Target
$1.70
+546.4% upside vs current
Range: $0.40 — $3.00
Altman Z
-39.2
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMTI buys
0
ORCC buys
0
No recent congressional trades found for AMTI or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMTIORCC
Forward yield760.46%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1810669.96M$21.4K
Annual income after 10y$1,438,546,236,154.04$1.04
Total dividends collected$1780986.19M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$1.70$16.00

Year-by-year: AMTI vs ORCC ($10,000, DRIP)

YearAMTI PortfolioAMTI Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$86,746$76,045.63$11,190$489.61+$75.6KAMTI
2$709,325$616,507.07$12,229$256.01+$697.1KAMTI
3$5,470,398$4,711,420.77$13,216$130.74+$5.46MAMTI
4$39,811,308$33,957,981.79$14,207$66.02+$39.80MAMTI
5$273,562,787$230,964,686.86$15,234$33.17+$273.55MAMTI
6$1,775,955,421$1,483,243,239.55$16,317$16.62+$1775.94MAMTI
7$10,899,466,861$8,999,194,560.48$17,468$8.32+$10899.45MAMTI
8$63,279,465,088$51,617,035,546.83$18,695$4.16+$63279.45MAMTI
9$347,779,178,316$280,070,150,671.65$20,006$2.08+$347779.16MAMTI
10$1,810,669,956,952$1,438,546,236,154.04$21,407$1.04+$1810669.94MAMTI

AMTI vs ORCC: Complete Analysis 2026

AMTIStock

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Full AMTI Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this AMTI vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMTI vs SCHDAMTI vs JEPIAMTI vs OAMTI vs KOAMTI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.